K-Ras mutation and prognosis of colorectal cancer: A meta-analysis

Hepato-Gastroenterology

Volumn 62, Issue 137, 2015, Pages 19-24

  Rui, Yuanyi ^a   Wang, Cun ^a   Zhou, Zongguang ^a   Zhong, Xi ^a   Yu, Yongyang ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

Colorectal cancer; Gene mutation; K ras; Metaanalysis; Survival outcome

Indexed keywords

ARTICLE; CANCER PROGNOSIS; CANCER RISK; CANCER SURVIVAL; CODON; COLORECTAL CANCER; DISEASE FREE SURVIVAL; GENE MUTATION; ONCOGENE K RAS; OVERALL SURVIVAL; PRIORITY JOURNAL; ANIMAL; CHI SQUARE DISTRIBUTION; COLORECTAL NEOPLASMS; GENETIC PREDISPOSITION; GENETICS; HUMAN; META ANALYSIS; MORTALITY; MUTATION; PATHOLOGY; PHENOTYPE; PROGNOSIS; RISK; RISK FACTOR;

KRAS PROTEIN, HUMAN; ONCOPROTEIN; RAS PROTEIN;

ANIMALS; CHI-SQUARE DISTRIBUTION; COLORECTAL NEOPLASMS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MUTATION; ODDS RATIO; PHENOTYPE; PROGNOSIS; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; RISK FACTORS;

EID: 84928576847     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: 10.5754/hge10727     Document Type: Article

References (46)

1. Jemal A, Siegel R, Xu J, Ward E: Cancer Statistics, 2010. CA Cancer J Clin 2010; 60(5):277-300.
2. Ferlay J, Autier P, Boniol M, et al.: Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 2007; 8(3):581-92.
3. Yang L, Parkin DM, Li LD, Chen YD, Bray F: Estimation and projection of the national profile of cancer mortality in China: 1991-2005. Br J Cancer 2004; 90(11): 2157-2166.
4. Barbacid M: Ras genes. Annu Rev Biochem 1987; 56:779-827.
5. Macara IG, Lounsbury KM, Richards SA, et al.: The Ras superfamily of GTPase. The FASEB Journal 1996; 10:625-630.
6. Bos JL: Ras oncogenes in human cancer: a review. Cancer Research 1989; 49:4682-4689.
7. Fearon ER, Vogelstein B: A genetic model for colorectal tumorigenesis. Cell 1990; 61(5):759-767.
8. Boughdady IS, Kinsella AR, Haboubi NY, Schofield PF: K-ras gene mutation in adenomas and carcinomas in colon. Surg Oncol. 1992; 1(4):275-282.
9. Finkelstein SD, Sayegh R, Christensen S, Swalsky PA: Genotypic classification of colorectal adenocarcinoma. Biologic behaviour correlates with K-ras-2 mutation type. Cancer 1993; 71(12):3827-3838.
10. Breivik J, Meling GI, Spurkland A, Rognum TO, Gaudernack G: K-ras mutation in colorectal cancer: relations to patient age, sex and tumor location. Br J Cancer 1994; 69(2): 367-371.
11. Vogelstein B, Fearon ER, Hamilton SR, et al.: Genetic alterations during colorectal-tumor development. N Engl J Med. 1988; 319(9):525-532.
12. Shaw P, Tardy S, Benito E, Obrador A, Costa J: Occurrence of Ki-ras and p53 mutations in primary colorectal tumors. Oncogene 1991;6(11):2121-2128.
13. Nagata Y, Abe M, Kobayashi K, et al.: Glycine to aspartic acid mutations at codon 13 of the c-Ki-ras gene in human gastrointestinal cancers. Cancer Res 1990; 50(3):480-482.
14. Amado RG, Wolf M, Peeters M, Van Cutsem E, et al.: Wildtype KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008; 26(10):1626-1634.
15. Karapetis CS, Khambata-Ford S, Jonker DJ, et al.: K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008; 359(17):1757-1765.
16. Lièvre A, Bachet JB, Boige V, et al.: KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 2008; 26(3):374-379.
17. Higgins JPT, Green S, eds: Cochrane handbook for systematic reviews of interventions 5.0.1 (updated September 2008). Chichester UK: Wiley, 2006. The Cochrane library.
18. Lee JC, Wang ST, Lai MD, Lin YJ, Yang HB: K-ras gene mutation is a useful predictor of the survival of early stage colorectal cancers. Anticancer Res 1996; 16(6B):3839-3844.
19. Hardingham J, Butler W, Roder D, et al.: Somatic mutations, acetylator status, and prognosis in colorectal cancer. Gut. 1998; 42(5): 669-672.
20. Luna-Pérez P, Segura J, Alvarado I, et al.: Specific c-K-ras gene mutations as a tumor-response marker in locally advanced rectal cancer treated with preoperative chemoradiotherapy. Ann Surg Oncol. 2000; 7(10):727-731.
21. Andreyev HJN, Norman AR, Cunningham D, et al.: Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II'study. Br J Cancer 2001; 85(5): 692-696.
22. Belly RT, Rosenblatt JD, Steinmann M, et al.: Detection of mutated K12-ras in histologically negative lymph nodes as an indicator of poor prognosis in stage II colorectal cancer. Clin Colorectal Cancer 2001; 1(2):110-6.
23. Bleeker WA, Hayes VM, Karrenbeld A, et al.: Prognostic significance of K-ras and TP53 mutations in the role of adjuvant chemotherapy on survival in patients with Dukes C colon cancer. Dis Colon Rectum 2001; 44(3):358-363.
24. Esteller M, Gonzalez S, Risques RA, et al.: K-ras and p16 aberrations confer poor prognosis in human colorectal cancer. J Clin Oncol 2001; 19(2):299-304.
25. Pan ZZ, Wan DS, Chen G, Li LR, Lu ZH, Huang BJ: Co-mutation of p53, K-ras genes and accumulation of p53 protein and its correlation to clinicopathological features in rectal cancer. World J Gastroenterol 2004; 10(24):3688-3690.
26. Conlin A, Smith G, Carey FA, Wolf CR, Steele RJ: The prognostic significance of K-ras, p53, and APC mutations in colorectal carcinoma. Gut 2005; 54(9):1283-1286.
27. Krtolica K, Krajnovic M, Usaj-Knezevic S, et al.: Comethylation of p16 and MGMT genes in colorectal carcinoma: correlation with clinicopathological features and prognostic value. World J Gastroenterol 2007; 13(8):1187-1194.
28. Poehlmann A, Kuester D, Meyer F, et al.: K-ras mutation detection in colorectal cancer using the Pyrosequencing technique. Pathol Res Pract 2007; 203(7):489-497.
29. Etienne-Grimaldi MC, Formento JL, et al.: K-Ras mutations and treatment outcome in colorectal cancer patients receiving exclusive fluoropyrimidine therapy. Clin Cancer Res 2008; 14(15):4830-4835.
30. Chang YS, Yeh KT, Chang TJ, et al.: Fast simultaneous detection of K-RAS mutations in colorectal cancer. BMC Cancer. 2009; 9:179.
31. Bazan V, Migliavacca M, Zanna I, et al.: Specific codon 13 K-ras mutations are predictive of clinical outcome in colorectal cancer patients, whereas codon 12 K-ras mutations are associated with mucinous histotype. Ann Oncol 2002; 13(9):1438-1446.
32. Lee S, Cho NY, Choi M, et al.: Clinicopathological features of CpG island methylator phenotype-positive colorectal cancer and its adverse prognosis in relation to KRAS/BRAF mutation. Pathol Int 2008; 58(2):104-113.
33. Etoh T, Ueo H, Inoue H, et al.: Clinical significance of K-Ras mutations in intraoperative tumor drainage blood from patients with colorectal carcinoma. Ann Surg Oncol. 2001; 8(5):407-412.
34. Yamazaki K, Hanami K, Nagao T, Asoh A, Sugano I, Ishida Y: Increased cyclin D1 expression in cancer of the ampulla of Vater: relevance to nuclear beta catenin accumulation and k-ras gene mutation. Mol Pathol. 2003; 56(6):336-341.
35. Mendelsohn J, Baselga J: The EGF receptor family as targets for cancer therapy. Oncogene 2000; 19(56):6550-6565.
36. Mellstedt H: Monoclonal antibodies in human cancer. Drugs Today (Barc) 2003; 39 Suppl C:1-16.
37. Salomon DS, Brandt R, Ciardiello F, Normanno N: Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 1995; 19(3):183-232.
38. Porebska I, Harlozinska A, Bojarowski T: Expression of the tyrosine kinase activity growth factor receptors (EGFR, ERB B2, ERB B3) in colorectal adenocarcinomas and adenomas. Tumour Biol 2000; 21(2):105-115.
39. Moroni M, Veronese S, Benvenuti S, et al.: Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. Lancet Oncol 2005; 6(5):279-286.
40. Lièvre A, Bachet JB, Le Corre D, et al.: KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 2006; 66(8):3992-3995.
41. Lièvre A, Bachet JB, Boige V, et al.: KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 2008; 26(3):374-379.
42. Karapetis CS, Khambata-Ford S, Jonker DJ, et al.: K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008; 359(17):1757-1765.
43. Khambata-Ford S, Garrett CR, Meropol NJ, et al.: Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol 2007; 25(22):3230-3237.
44. Van Cutsem E, Lang I, D'haens G, et al.: KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLF1RI with or without cetuximab: The CRYSTAL experience. J Pancreas 2010; 11(4):328-330.
45. Jonker DJ, O'Callaghan CJ, Karapetis CS, et al.: Cetuximab for the treatment of colorectal cancer. N Engl J Med. 2007; 357(20):2040-2048.
46. Ibrahim EM, Zekri JM, Bin Sadiq BM: Cetuximab for the treatment of colorectal cancer: a meta-analysis of the effect of K-ras mutations. Int J Colorectal Dis 2010; 25(6):713-721.